$AGTC - On our trading list. has a huge up day on what looks like positive drug news. 3 Analysts weighed in with positive ratings or raised price targets. Stock exploded higher! Up 110%!Applied Genetic price target raised to $16 from $9 at BMO CapitalBMO Capital analyst Matthew Luchini raised his price target for Applied Genetics to $16 from $9 following release of Phase 1/2 six-month data in XLRP. The analyst believes latest data provide additional de-risking to the program and, given his increased confidence, he is raising probability of success to 55% from 25%. Further, Luchini believes the data is a clear win for the company, showing sustained benefit in visual sensitivity and stable/improving visual function while maintaining a clean safety profile. With Phase 1/2 ACHM data expected this month and additional XLRP data in the second half of 2020, he sees potential for further upside. The analyst has an Outperform rating on the shares.Applied Genetic opportunity in XLRP becoming clearer, says WedbushApplied Genetic Technologies presented updated, positive six-month interim data from its Phase 1/2 study of centrally-treated X-linked retinitis pigmentosa patients, Wedbush analyst David Nierengarten tells investors in a research note Importantly, patients are experiencing durable improvements in both visual sensitivity and acuity since the interim update last September, adds the analyst. Given the results to date, he views Applied Genetic as the market leader in X-linked retinitis pigmentosa. Nierengarten reiterates an Outperform rating on Applied Genetic with a $12 price target and notes the stock is one of his top picks for 2020.Applied Genetic analyst commentary at H.C. WainwrightApplied Genetics' XLRP data supports strong pivotal design, says H.C. Wainwright. H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $18 price target on Applied Genetic after the company announced "positive" six-month data form its ongoing Phase 1/2 study in patients with X-Linked Retinitis Pigmentosa, saying the data supports a "strong" pivotal design. Pantginis said he believes these "highly anticipated" data confirmed his expectations on the performance of the company's therapy and boosted investors' confidence in the company's assets. The analyst added that an upcoming meeting with the FDA is expected to provide critical guidance on endpoints, size and statistics, randomization protocol, and bilateral dosing. $AGTC, Applied Genetic Technologies Corporation / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page